← Leaderboards
Alan Clayton Sartorelli
Yale University
$9,274,853
Attributed
$9,274,853
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $889.5K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$9,274,853 · 7
By mechanism
R01$7,698,261 · 6
P01$1,576,592 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Peter M Glazer$37,467,142
- Ranjit Bindra$5,884,099
- Jeffrey Louis Gustafson$3,460,241
- William L Jorgensen$1,008,000
- William A Mitch$1,695,570
Others in their field
Top investigators on “Prodrugs”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Robert Turner Schooley · University Of Colorado Denver$47,231,917
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$26,039,397
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Kevin V Grimes · Stanford University$14,783,804
Research focus
ProdrugsNeoplastic CellCrosslinkHypoxiaHydrazinesDesignResistanceGuanineTransplantationSolid NeoplasmAlkylating AgentsWaterHydrazineTumorCellsO(6)-Methylguanine-Dna MethyltransferasePositioning AttributeCarmustineAnalogLeadMeasurementEnzymesDrug-SensitiveEthane
Grant awards (32)
Hypoxia-Activated O6-Benzylguanine Prodrugs$284,988
R01 · FY2012 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$6,919
P01 · FY2012 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$316,968
P01 · FY2011 · CA · contact PI
Hypoxia-Activated O6-Benzylguanine Prodrugs$284,988
R01 · FY2011 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$329,043
P01 · FY2010 · CA · contact PI
Hypoxia-Activated O6-Benzylguanine Prodrugs$293,802
R01 · FY2010 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$322,566
P01 · FY2009 · CA · contact PI
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines$295,408
R01 · FY2009 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$309,654
P01 · FY2008 · CA · contact PI
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines$294,589
R01 · FY2008 · CA · contact PI
Hypoxia-Activated O6-Benzylguanine Prodrugs$285,244
R01 · FY2008 · CA · contact PI
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines$294,515
R01 · FY2007 · CA · contact PI
TUMOR SELECTIVE INACTIVATION OF THE REPAIR PROTEIN AGT$291,442
P01 · FY2007 · CA · contact PI
Hypoxia-Activated O6-Benzylguanine Prodrugs$285,244
R01 · FY2007 · CA · contact PI
Development of Anticancer 1,2-Bis(sulfonyl)hydrazines$303,311
R01 · FY2006 · CA · contact PI
Hypoxia-Activated O6-Benzylguanine Prodrugs$292,875
R01 · FY2006 · CA · contact PI
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT$367,875
R01 · FY2005 · HD
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES$327,409
R01 · FY2005 · CA
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT$367,875
R01 · FY2004 · HD
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES$327,409
R01 · FY2004 · CA
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT$367,875
R01 · FY2003 · HD
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES$327,409
R01 · FY2003 · CA
MECHANISMS OF RESISTANCE TO MITOMYCIN ANTIBIOTICS$262,704
R01 · FY2003 · CA
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT$367,875
R01 · FY2002 · HD
DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES$327,409
R01 · FY2002 · CA
MECHANISMS OF RESISTANCE TO MITOMYCIN ANTIBIOTICS$255,593
R01 · FY2002 · CA
ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT$367,875
R01 · FY2001 · HD
MECHANISMS OF RESISTANCE TO MITOMYCIN ANTIBIOTICS$248,690
R01 · FY2001 · CA
TERMINAL DIFFERENTIATION AS A THERAPEUTIC APPROACH$198,013
R01 · FY2001 · CA
MECHANISMS OF RESISTANCE TO MITOMYCIN ANTIBIOTICS$242,026
R01 · FY2000 · CA
PRODRUGS TARGETING HYPOXIC TUMOR CELLS$234,070
R01 · FY2000 · CA
TERMINAL DIFFERENTIATION AS A THERAPEUTIC APPROACH$193,190
R01 · FY2000 · CA